JiMED

GiMED Inc. is a pioneering medical venture founded by Shirata Shinnobu of Osaka University, specializing in the development and social implementation of wireless embedded Brain-Computer Interface (BCI) technology. The company focuses on leveraging advanced AI and buried devices to accurately read brain activity, enabling users to control devices simply through thought. GiMED's primary market includes patients with Amyotrophic Lateral Sclerosis (ALS), aiming to significantly improve their communication abilities and overall quality of life (QOL). The business model revolves around the commercialization of its BCI technology, targeting healthcare providers, research institutions, and directly serving patients. Revenue is generated through the sale of BCI devices, software solutions, and ongoing support services. By integrating cutting-edge AI with medical technology, GiMED is positioned at the forefront of neurotechnology innovation.

Keywords: BCI, ALS, AI, brain activity, communication, quality of life, neurotechnology, healthcare, medical devices, innovation.